Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LTI 291

Next Previous
X
Search
Drug Profile

LTI 291

Alternative Names: BIA 28-6156/LTI-291; LTI-00291; LTI-291

Latest Information Update: 28 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lysosomal Therapeutics
  • Developer BIAL; Lysosomal Therapeutics
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Glucosylceramidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in United Kingdom (PO)
  • 31 Mar 2023 Phase-II clinical trials in Parkinson's disease (In adults, In the elderly) in Canada, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, Sweden, United Kingdom (PO) (NCT05819359)
  • 31 Mar 2023 Phase-II clinical trials in Parkinson's disease (In adults, In the elderly) in United Kingdom, Sweden, Spain, Portugal, Portugal, Poland, Netherlands, Italy, Germany, France, Canada (PO) (NCT05819359)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top